Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.50 |
| ▸ | VCP | P55072 | 5/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2363119 | 0.98 | SYK (0.53) | SYKPLA2G7VCPNR4A1ALDH1A1 | |
| SCHEMBL1091636 | 0.81 | ALDH1A1 (0.58) | PLA2G7VCPALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL14881017 | 0.81 | MEN1 (0.54) | PLA2G7ALDH1A1HTTSMN1; SMN2GAA | |
| SCHEMBL5762561 | 0.81 | PLA2G7 (0.58) | PLA2G7ALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL2981886 | 0.81 | ALDH1A1 (0.61) | SYKPLA2G7ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL899534 | 0.81 | SMN1; SMN2 (0.61) | PLA2G7ALDH1A1HTTSMN1; SMN2GAA | |
| SCHEMBL722560 | 0.80 | RAB9A (0.59) | PLA2G7ALDH1A1HTTSMN1; SMN2GAA | |
| SCHEMBL17397927 | 0.80 | PLA2G7 (0.49) | PLA2G7VCPALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1180559 | 0.79 | GAA (0.55) | SMN1; SMN2GAAMAPTLMNAMEN1 | |
| SCHEMBL3042388 | 0.79 | MBD2 (0.55) | SYKPLA2G7ALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018209-B2 | Compounds and methods for the treatment of viruses and cancer | YALE UNIVERSITY (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2766359-A2 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES | Ambit Biosciences Corporation (US) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013056070-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | YALE UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2007038387-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER | YALE UNIVERSITY (US) | 2007-04-05 | — | — | WO | disclosed |
| CN-1337961-A | Heteroaryl amidines, methyl amidiues and guanidines as protease inhibitors | DIMENSIONAL PHARM INC (US) | 2002-02-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | RCOR1, RCOR3, CCNT1 | SYK 3473/4885PLA2G7 4400/4885VCP 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.